home / stock / glue / glue articles
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast...
BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing ...
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrad...
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09%...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0....
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OT...
Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies...
News, Short Squeeze, Breakout and More Instantly...
Monte Rosa Therapeutics Inc. Company Name:
GLUE Stock Symbol:
NASDAQ Market:
Monte Rosa Therapeutics Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside cha...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 202...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected ...